Process improvements and growing adoption enable AlphaThera to reduce prices for larger-volume orders, helping research budgets go further at a time of increasing industry-wide costs.
At a time when research budgets are becoming stretched as a result of rising costs across the life sciences industry, AlphaThera is reducing prices for bulk orders of its oYo-Link® antibody conjugation reagents.
The cost of key research inputs has risen substantially in recent years. US producer price data show that prices for biological products and analytical laboratory instruments have increased by approximately 26% since 2020, while basic organic chemical prices have risen by around 35%.[1–3] These increases come as researchers face growing pressure to maximize increasingly constrained research budgets.[4]
Against this backdrop, AlphaThera is reducing prices on larger-volume orders by 15-50%, depending on scale of order. The new pricing has been made possible by continued improvements to AlphaThera’s manufacturing and operational processes, combined with growing interest in, and adoption of, its site-specific antibody conjugation technology. As demand has increased, AlphaThera has been able to achieve greater efficiencies at scale and is passing these savings directly on to researchers through lower prices on larger-volume orders.
“As interest in oYo-Link has grown, we’ve been able to improve our processes and achieve greater efficiencies at scale,” commented Dr. Feifan Yu, CSO at AlphaThera. “We want our customers to benefit from those improvements too. At a time when research organizations are seeing costs increase across so many areas, we’re pleased to be able to reduce prices for researchers looking to adopt oYo-Link® for larger-scale conjugation.”
oYo-Link® enables covalent and site-specific conjugation of antibodies to custom oligonucleotides, fluorescent proteins, enzymes, biotin, drugs and other payloads. The technology is designed to simplify antibody conjugation to just two steps – mix and illuminate – reducing the time and complexity traditionally associated with producing site-specific antibody conjugates.
oYo-Link® technology is also compatible with common antibody buffers, while its site-specific conjugation approach minimizes impact on antibody binding and produces homogeneous conjugates for more consistent assay performance.
Alongside making its technology more accessible, AlphaThera places a strong emphasis on customer service and technical support. Researchers have direct access to expert technical advice from the AlphaThera team, helping them select the right reagents, optimize their conjugation strategy and get the most from oYo-Link® for their specific application.
The reduced larger-volume pricing, combined with expert technical support for every customer, reflects AlphaThera’s continued focus on making site-specific antibody conjugation more accessible, straightforward and cost-effective as demand for antibody conjugates grows across life science research.
References
[1] U.S. Bureau of Labor Statistics. Producer Price Index by Commodity: Chemicals and Allied Products: Biological Products, Including Diagnostics (WPU0637). Federal Reserve Bank of St. Louis, FRED.
[2] U.S. Bureau of Labor Statistics. Producer Price Index by Industry: Analytical Laboratory Instrument Manufacturing (PCU334516334516). Federal Reserve Bank of St. Louis, FRED.
[3] U.S. Bureau of Labor Statistics. Producer Price Index by Commodity: Chemicals and Allied Products: Basic Organic Chemicals (WPU0614). Federal Reserve Bank of St. Louis, FRED.
[4] Coppola M, House TO, Tsai JW. Maximizing grant funding: strategies for negotiating laboratory pricing. Trends in Biochemical Sciences. 2025;50(4):281–284. doi:10.1016/j.tibs.2025.01.008